Safety
Compounded GLP-1 safety and current FDA concerns
Compounded semaglutide and tirzepatide are not FDA-approved medicines. A prescription can be patient-specific, but it still needs an appropriate medical rationale, compliant production, and careful dispensing.
What FDA approval does and does not mean
FDA reviews approved drugs for safety, effectiveness, and quality before marketing. Compounded medicines do not undergo that review. Descriptions such as pharmaceutical-grade, doctor prescribed, or made in a registered facility do not change that approval status.
FDA advises using a compounded drug only when a patient's medical needs cannot be met by an approved drug. Obtain a prescription through a clinician and fill it through a state-licensed pharmacy. These checks should be completed for the actual product, not inferred from a platform's overall reputation.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
The shortage exception changed
FDA's current clarification explains restrictions after the tirzepatide and semaglutide injection shortages were resolved. Section 503A patient-specific compounding and section 503B outsourcing have different conditions; neither is a blanket permission to mass-market essentially copies.
Adding a vitamin, changing a dose slightly, or describing a formula as personalized does not by itself establish that an exception applies. Ask the clinician and pharmacy to explain the medically necessary difference for the patient and the applicable pathway.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes
Formulation and dosing concerns
FDA warns against semaglutide salt forms such as sodium and acetate because they differ from the active ingredient in approved drugs. It also reports dosing errors and adverse events associated with unapproved GLP-1 products.
Vials need concentration-specific instructions, and compounded oral products need their own evidence. Do not assume that approved-drug dosing, absorption, storage, or trial outcomes apply to a different formula. Injections with uncertain sourcing or inadequate labeling deserve a pharmacy review before use.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
A practical conversation before treatment
Ask why an approved product cannot meet the medical need, who prescribes, who compounds and dispenses, what ingredients are present, and how the dose is measured. Discuss alternatives, coverage problems, monitoring, and what happens if side effects or a quality concern arise.
This page does not determine whether a particular prescription meets every legal condition or declare an unverified provider's product unlawful. The point is to make the unresolved questions visible and to avoid treating marketing as approval evidence.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Quality claims answer different questions
FDA approval, state pharmacy licensing, facility registration, and a laboratory certificate describe different things. Approval concerns the particular manufactured drug and its reviewed evidence. Licensing identifies authorization to practice. Registration is not product approval. A certificate may describe a tested sample without establishing the identity, sterility, or clinical appropriateness of every dispensed vial.
Ask which claim a seller is making and what document supports it. Phrases such as "same active ingredient" or "pharmaceutical grade" do not resolve approval, formulation, or outcome questions. Also distinguish approved generic products from compounded preparations. An unapproved compound cannot borrow a branded drug's weight-loss, cardiovascular, kidney, or liver indication just because the ingredient language is similar. Evidence should follow the actual formulation and medical purpose.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Check the product that arrives, not just the enrollment page
Read the pharmacy label and confirm that it matches the prescription, including the ingredients, concentration, route, and intended dose. Obtain clear storage and beyond-use instructions, and contact the pharmacy if packaging is damaged or temperature exposure is uncertain. A shipment notification proves dispatch, not that the contents have been checked or are appropriate to use.
For multidose vials, ask for the exact volume and syringe directions. A concentration change can alter the required volume even if the prescribed milligrams are unchanged. Do not transfer an old unit instruction to a new vial. Compounded oral preparations require their own absorption and efficacy evidence; the fasting rules or trial results of an approved semaglutide tablet do not validate drops, lozenges, or a different capsule.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA BeSafeRx: checking an online pharmacy
Make the unresolved decision visible to the clinician
If compounding is proposed, ask why an approved product cannot meet the medical need, which pharmacy prepares and dispenses it, what applicable pathway is used, and what evidence supports the formula. Discuss approved alternatives and access difficulties honestly. A coverage denial is a practical problem, but does not by itself settle the medical or legal basis for a compound.
If a dosing or quality problem is suspected, contact the prescriber and pharmacist promptly and keep the packaging and administration details. Significant symptoms need medical assessment, and FDA MedWatch is a route for reporting suspected adverse events or product problems. The aim is not to label every compounded prescription the same; it is to ensure the actual formulation, rationale, measurement, and follow-up are understood before marketing claims become treatment assumptions.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.